Quarterly ResultAug 13, 2026, 10:36 AM
Valneva H1 2026 Product Sales €64M; Reaffirms FY Guidance
AI Summary
Valneva reported H1 2026 product sales of €64.0 million and total revenues of €65.8 million, a decrease from H1 2025, primarily due to planned wind-down of third-party sales and expected phasing. The company reaffirmed its full-year guidance of €135-150 million for product sales. Valneva maintained a strong cash position of €121.5 million, reflecting disciplined management and proceeds from a recent offering, and implemented a restructuring program. Regulatory decisions for its Lyme disease vaccine candidate are expected within the next twelve months, with Pfizer expressing optimism.
Key Highlights
- H1 2026 product sales were €64.0 million, down from €91.0 million in H1 2025.
- H1 2026 total revenues were €65.8 million, down from €97.6 million in H1 2025.
- Net loss for H1 2026 was €63.3 million, compared to €20.8 million in H1 2025.
- Cash and cash equivalents stood at €121.5 million as of June 30, 2026.
- Reaffirmed full-year 2026 product sales guidance of €135 million to €150 million.
- Implemented a restructuring program to reduce cash burn and streamline operations.
- Regulatory decisions for Lyme disease vaccine candidate expected in next 12 months.
- Sale of Nantes site for €6.2 million expected to close in September 2026.
Price Impact
More from VALN